In light of recent debate in the United States, the Institute of Health Visiting reaffirms its longstanding support for childhood immunisations and for the UK vaccination schedule, which is based on robust scientific evidence and includes the combined MMR vaccine as the safest and most effective way to protect children against measles, mumps and rubella.
Professor Helen Bedford, Professor of Children’s Health, UCL Great Ormond Street Institute of Child Health, and Expert Adviser for Immunisations at the Institute of Health Visiting, said:
“MMR vaccine has been used in the USA for over 50 years since the early 1970s and in the UK since 1988. It is highly effective and has an excellent safety profile. Like all vaccines, it can give rise to mild side effects such as fever, feeling off colour and, as it is a live vaccine, symptoms of mild measles, mumps and rubella; these are short lasting and not infectious. Occasionally side effects are more severe, such as fits. The side effects of vaccines need to be balanced against the impact and complications of the diseases they prevent.
“Measles, mumps and rubella all have serious effects. We have already seen child deaths from measles this year in the UK. A large body of research conducted over the past two decades has found strong evidence of no link between MMR vaccine and autism. The vaccine has saved, and continues to save, millions of lives. The three vaccines have never been administered as separate doses to young children as part of vaccination policy so its safety and effectiveness are unproven. However, just the inevitable delay gaining protection such a regimen would involve, would be a serious step backwards for protecting our children’s health.”
The UK Health Security Agency (UKHSA) reported 953 laboratory-confirmed measles cases in England between 1 January and 3 August 2026, with the majority of cases occurring in unvaccinated children. The tragic deaths of two children from measles in England this year are a stark reminder that measles is not a harmless childhood illness and that maintaining high uptake of the MMR vaccine remains essential to protecting children and communities – and health visiting teams have a vital role to play in ensuring that families have access to accurate information and reducing barriers to vaccine uptake.
For further information on supporting families to make informed choices and find links to the latest evidence and national guidance, please see:
Please note that GPPs are available to iHV members only. If you’re not a member, please join us to get access to all of our resources.
Whilst the controversy in the USA surrounds the administration of the MMR vaccine – both the MMR and MMRV are offered to children in the UK, depending on the age of the child (following the introduction of MMRV in January 2026 for babies and younger children). Please see the latest .gov.uk guidance, with links to the Green Book and information for healthcare practitioners on the current schedule here.



